滨会生物冲刺港股:年亏1.1亿 乐普生物与扬子江药业是股东 估值超30亿

雷递
Oct 01, 2025

雷递网雷建平 10月1日武汉滨会生物科技股份有限公司(简称:“滨会生物”)日前递交招股书,准备在港交所上市。滨会生物曾在2023年完成一轮融资,投后估值为32.2亿元。滨会生物是继芯微电子、艾米森之后,又一家准备在港股上市的武汉企业。年亏损1.1亿滨会生物成立于2010年,是一家溶瘤病毒疗法生物科技公司,致力于创新癌症免疫疗法的发现、开发及商业化。滨会生物自主研发的核心产品BS001(OH2注射液...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10